Adilson Kleber Ferreira

• Abstract

  Lung cancer is one of the most lethal cancers in the world, and development of new drugs is essential for the control of this disease. The most abundant phospholipid in the inner cell membranes is phosphatidylethanolamine (PE), which is essential for the cell growth, cytokinesis, apoptosis and autophagy. The main route of PE synthesis by the CDP ethanolamine Kennedy pathway is regulated b…

  Development of Pet-1 as a small molecule inhibitor of the CDP- ethanolamine Kennedy pathway with therapeutic potential for Non- Small Cell Lung Cancer, AP.PIPE

• Abstract

  Lung cancer is the leading cause of death from cancer worldwide. Chemotherapy protocols currently used for the treatment of non-small cell lung cancer (NSCLC) have still shown a limited response. Indeed, the resistance to chemotherapy remains the major problem for the treatment of advanced disease. In this regard, of utmost importance is the development of new, useful compounds that are e…

  Development of new drug candidate for the treatment of non-small cell lung cancer: CHY-1 as a novel inhibitor of autophagy and prototype of a novel class of inhibitors of the enzyme CTP: phosphoethanolamine citidililtransferase, AP.JP

• Development of Pet-1 as a small molecule inhibitor of the CDP- ethanolamine Kennedy pathway with therapeutic potential for Non- Small Cell Lung Cancer, BP.PIPE

• Abstract

  Cancer remains a challenge to global public health, comprising the second leading cause of mortality worldwide. Currently, therapeutic strategies such as immunotherapy have returned hope to thousands of patients and oncologists who are battling the disease. There are several types of immunotherapy sharing a goal in common, to empower the patient's immune system to fight the tumor. However…

  Rational design of a STING agonist as a model for the implementation of a platform for the development of new immunotherapies against cancer, BP.PD

• Abstract

  Lung cancer is the leading cause of death from cancer worldwide. Chemotherapy protocols currently used for the treatment of non-small cell lung cancer (NSCLC) have still shown a limited response. Indeed, the resistance to chemotherapy remains the major problem for the treatment of advanced disease. In this regard, of utmost importance is the development of new, useful compounds that are e…

  Development of new drug candidate for the treatment of non-small cell lung cancer: CHY-1 as a novel inhibitor of autophagy and prototype of a novel class of inhibitors of the enzyme CTP: phosphoethanolamine citidililtransferase, BP.MS

(Only some records are available in English at this moment)

• Abstract

  Non-small cell lung cancer (NSCLC) is therapeutically limited and despite the successful use of small molecule inhibitors there are many resistant patients to current chemotherapeutics, and this remains a major problem in the treatment of advanced disease. In this regard, it is of utmost a development of new useful compounds, efficient and selective that possibility the treatment of patie…

  Evaluation of antitumor effects of new antineoplastic phospholipids analogous an inhibitor of the enzyme CtP: phosphoethanolamine citidililtransferase in non-small cell lung cancer, BE.EP.PD